How Corneal Collagen Crosslinking Halts Keratoconus

Keratoconus is a progressive condition in which the cornea gradually thins and bulges into an irregular cone shape, distorting vision. Left untreated, it can advance to a point where glasses and contact lenses no longer provide useful correction, and a corneal transplant may become necessary. Corneal collagen crosslinking (CXL) is the only treatment proven to halt this progression, and understanding how it works can help patients appreciate why early intervention matters so profoundly.

Understanding the Weakened Cornea

The cornea derives its strength from a lattice of collagen fibres arranged in precise layers. In keratoconus, the chemical bonds between these fibres—known as crosslinks—are deficient, allowing the cornea to weaken and deform under normal intraocular pressure. Research has demonstrated that keratoconic corneas possess approximately 60% fewer crosslinks compared to healthy corneas. This fundamental structural weakness is what crosslinking directly targets.

The condition typically presents during the teenage years or early twenties, progressing at varying rates. Some patients experience rapid deterioration over months, while others change slowly over years. Regardless of pace, the trajectory without treatment is generally downward—once collagen bonds fail, they do not spontaneously recover. This makes timing of intervention critically important.

The Crosslinking Procedure: How It Works

The principle behind CXL is elegant in its simplicity. Riboflavin (vitamin B2) drops are applied to the cornea, saturating the collagen matrix. Controlled ultraviolet-A light is then applied for a precise duration. The interaction between UV-A and riboflavin generates reactive oxygen species that create new covalent bonds between adjacent collagen fibrils—essentially welding the structural framework back together at a molecular level.

The standard Dresden protocol involves removing the corneal epithelium (the thin surface layer) to allow riboflavin to penetrate the stroma effectively. The UV-A light is applied at 3 milliwatts per square centimetre for 30 minutes, delivering a total energy dose of 5.4 joules per square centimetre. This precise dosing has been extensively validated in clinical studies spanning over 15 years across multiple international centres.

Transepithelial (epi-on) crosslinking preserves the epithelium, reducing discomfort and speeding recovery. However, current evidence suggests the epithelium-off approach remains more reliably effective at halting progression, particularly in more advanced cases. Ms Menassa will discuss which approach is most appropriate for your individual situation.

What the Evidence Shows

Long-term data from European studies demonstrates that CXL successfully halts progression in over 90% of treated eyes at 10-year follow-up. Many patients also experience a modest improvement in corneal shape during the first year after treatment, as the newly strengthened cornea settles into a more regular configuration. These improvements, while not dramatic, can translate into better contact lens fitting and occasionally improved spectacle-corrected vision.

It is important to understand what crosslinking does and does not achieve. It stabilises the cornea, preventing further deterioration. It does not reverse existing keratoconus or restore the cornea to a normal shape. Patients with significant pre-existing distortion will still require contact lenses or, in some cases, other procedures to optimise their vision. The value of crosslinking lies in preserving what you have and preventing the need for corneal transplantation.

Recovery and What to Expect

Following the procedure, the epithelium regenerates over three to five days. During this healing period, patients experience discomfort, light sensitivity, and blurred vision. A bandage contact lens is placed to protect the surface, and antibiotic and anti-inflammatory drops are prescribed. Most patients return to normal activities within one to two weeks, though vision may continue to fluctuate for several months as the cornea stabilises and the new crosslinks mature.

The cornea typically reaches its final post-crosslinking shape by six to twelve months. During this period, contact lens fitting may need adjustment as the corneal topography settles. Follow-up appointments with Ms Menassa track your corneal measurements over time, confirming that the treatment has achieved stable crosslinking.

Why Early Intervention Matters

Ms Menassa trained in corneal crosslinking during her fellowship in Germany and Switzerland, where the technique was pioneered. She offers CXL at her Liverpool practice for patients with progressive keratoconus, providing the specialist assessment and surgical expertise this precise procedure demands. The single most important message about crosslinking is timing: the earlier it is performed in the course of keratoconus, the more corneal integrity is preserved. If you have been diagnosed with keratoconus, or suspect your vision is changing, seeking specialist assessment promptly gives you the best chance of maintaining your sight long-term.